The impact of anogenital warts on health-related quality of life: A 6-month prospective study

Sexually Transmitted Diseases

Volumn 38, Issue 10, 2011, Pages 949-956

  Drolet, Mélanie ^a   Brisson, Marc ^a,b   Maunsell, Elizabeth ^a,b   Franco, Eduardo L ^c   Coutlée, François ^d   Ferenczy, Alex ^c,e   Ratnam, Sam ^f   Fisher, William ^g   Mansi, James A ^h  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d NOTRE DAME HOSPITAL   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f Newfoundland and Labrador Public Health Laboratory   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANXIETY DISORDER; CANADA; CONDYLOMA ACUMINATUM; DEPRESSION; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SELF CONCEPT; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SEXUALITY; SHORT FORM 12; STATE TRAIT ANXIETY INVENTORY;

ADOLESCENT; ADULT; CANADA; CONDYLOMATA ACUMINATA; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; MALE; PAPILLOMAVIRUS VACCINES; PROSPECTIVE STUDIES; PUBLIC HEALTH; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; RECURRENCE; SELF CONCEPT; SEXUAL BEHAVIOR; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 80052971713     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3182215512     Document Type: Review

References (35)

1. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199:805-814.
2. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2010; 59:630-632.
3. Hoy T, Singhal PK, Willey VJ, et al. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009; 25:2343-2351.
4. Kliewer EV, Demers AA, Elliott L, et al. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis 2009; 36:380-386.
5. Woodhall SC, Jit M, Cai C, et al. Cost of treatment and QALYs lost due to genital warts: Data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis 2009; 36:515-521.
6. Castellsague X, Cohet C, Puig-Tintore LM, et al. Epidemiology and cost of treatment of genital warts in Spain. Eur J Public Health 2009; 19:106-110.
7. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2009; 85:111-115.
8. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: A study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007; 196:1447-1454. (Pubitemid 351411979)
9. Ireland JA, Reid M, Powell R, et al. The role of illness perceptions: Psychological distress and treatment-seeking delay in patients with genital warts. Int J STD AIDS 2005; 16:667-670. (Pubitemid 41527347)
10. Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008; 84:161-166. (Pubitemid 351871484)
11. Marra C, Ogilvie G, Gastonguay L, et al. Patients with genital warts have a decreased quality of life. Sex Transm Dis 2009; 36:258-260.
12. Pirotta M, Ung L, Stein A, et al. The psychosocial burden of human papillomavirus related disease and screening interventions. Sex Transm Infect 2009; 85:508-513.
13. Senecal M, Brisson M, Maunsell E, et al. Loss of quality of life associated with genital warts: Baseline analyses from a prospective study. Sex Transm Infect 2011; 87:209-215.
14. Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2:169-180. (Pubitemid 23203441)
15. Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care 2000; 38:115-121.
16. Gudex C, Dolan P, Kind P, et al. Health state valuations from the general public using the visual analogue scale. Qual Life Res 1996; 5:521-531. (Pubitemid 27006964)
17. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35:1095-1108. (Pubitemid 127453463)
18. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004; 42:851-859. (Pubitemid 39456916)
19. Saris-Baglama R, Dewey CJ, Chisholm G, et al. SF Health Outcomes Scoring Software User's Guide. Lincoln, RI: Quality-Metric Inc, 2004.
20. Marteau TM, Bekker H. The development of a six-item shortform of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992; 31(pt 3):301-306.
21. Hopman WM, Towheed T, Anastassiades T, et al; Canadian Multicentre Osteoporosis Study Research Group. Canadian normative data for the SF-36 health survey. CMAJ 2000; 163:265-271. (Pubitemid 30670667)
22. Hellsten C, Sjostrom K, Lindqvist PG. A 2-year follow-up study of anxiety and depression in women referred for colposcopy after an abnormal cervical smear. BJOG 2008; 115:212-218. (Pubitemid 350233618)
23. Forsberg C, Bjorvell H. Swedish population norms for the GHRI, HI and STAI-state. Qual Life Res 1993; 2:349-356. (Pubitemid 24011487)
24. Drolet M, Brisson M, Maunsell E, et al. The psychosocial impact of an abnormal cervical smear result: A prospective and comparative study. Psychooncology 2011; In press.
25. Mast TC, Zhu X, Demuro-Mercon C, et al. Development and psychometric properties of the HPV Impact Profile (HIP) to assess the psychosocial burden of HPV. Curr Med Res Opin 2009; 25:2609-2619.
26. Fairclough D. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC Press, 2002.
27. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10:407-415. (Pubitemid 20025670)
28. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005; 14:1523-1532. (Pubitemid 40848233)
29. Woodhall S, Jit M, Soldan K, et al. QOLIGEN: A multicentre study to investigate quality of life, duration of episode and treatment costs associated with genital warts. In: 26th International Papillomavirus Conference; July 3-8, 2010; Montreal, Quebec, Canada.
30. Hook EW III, Richey CM, Leone P, et al. Delayed presentation to clinics for sexually transmitted diseases by symptomatic patients. A potential contributor to continuing STD morbidity. Sex Transm Dis 1997; 24:443-448. (Pubitemid 27452556)
31. Hibbard JH, Pope CR. Gender roles, illness orientation and use of medical services. Soc Sci Med 1983; 17:129-137.
32. Sandman D, Simantov E, An C. Out of touch: American men and the health care system. Commonwealth Fund Men's and Women's health survey finding. Marc 2010. Available at http://www.usrf.org/breakingnews/Men-out-of-touch.pdf. Accessed January, 2011.
33. Kliewer E, Demers A, Elliott L, et al. Twenty Year Trends (1985-2004) in the Incidence and Prevalence of Anogenital Warts in Manitoba. Winnipeg, Manitoba: CancerCare Manitoba, 2008.
34. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191:731-738. (Pubitemid 40271061)
35. National Institute of Health and Clinical Excellence. Guide to the methods of technology appraisal. Available at: http://www.nice. org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed February 18, 2009.